Literature DB >> 31545987

Shared pathways for neuroprogression and somatoprogression in neuropsychiatric disorders.

Gerwyn Morris1, Basant K Puri2, Adam J Walker1, Michael Maes1, Andre F Carvalho3, Chiara C Bortolasci4, Ken Walder4, Michael Berk5.   

Abstract

Activated immune-inflammatory, oxidative and nitrosative stress (IO&NS) pathways and consequent mitochondrial aberrations are involved in the pathophysiology of psychiatric disorders including major depression, bipolar disorder and schizophrenia. They offer independent and shared contributions to pathways underpinning medical comorbidities including insulin resistance, metabolic syndrome, obesity and cardiovascular disease - herein conceptualized as somatoprogression. This narrative review of human studies aims to summarize relationships between IO&NS pathways, neuroprogression and somatoprogression. Activated IO&NS pathways, implicated in the neuroprogression of psychiatric disorders, affect the pathogenesis of comorbidities including insulin resistance, dyslipidaemia, obesity and hypertension, and by inference, metabolic syndrome. These conditions activate IO&NS pathways, exacerbating neuroprogression in psychiatric disorders. The processes whereby proinflammatory cytokines, nitrosative and endoplasmic reticulum stress, NADPH oxidase isoforms, PPARγ inactivation, SIRT1 deficiency and intracellular signalling pathways impact lipid metabolism and storage are considered. Through associations between body mass index, chronic neuroinflammation and FTO expression, activation of IO&NS pathways arising from somatoprogression may contribute to neuroprogression. Early evidence highlights the potential of adjuvants targeting IO&NS pathways for treating somatoprogression and neuroprogression.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aetiology; Cardiovascular disease; Diabetes; Disease progression; Inflammation; Mental disorders; Metabolic syndrome; Non-Communicable disorders; Obesity; Oxidative stress; Pathophysiology; Psychiatry; Staging; Treatment

Year:  2019        PMID: 31545987     DOI: 10.1016/j.neubiorev.2019.09.025

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  20 in total

1.  Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial.

Authors:  Michael Berk; Robyn L Woods; Mark R Nelson; Raj C Shah; Christopher M Reid; Elsdon Storey; Sharyn Fitzgerald; Jessica E Lockery; Rory Wolfe; Mohammadreza Mohebbi; Seetal Dodd; Anne M Murray; Nigel Stocks; Paul B Fitzgerald; Catherine Mazza; Bruno Agustini; John J McNeil
Journal:  JAMA Psychiatry       Date:  2020-10-01       Impact factor: 21.596

2.  Patterns of Association between Depressive Symptoms and Chronic Medical Morbidities in Older Adults.

Authors:  Bruno Agustini; Mojtaba Lotfaliany; Robyn L Woods; John J McNeil; Mark R Nelson; Raj C Shah; Anne M Murray; Michael E Ernst; Christopher M Reid; Andrew Tonkin; Jessica E Lockery; Lana J Williams; Michael Berk; Mohammadreza Mohebbi
Journal:  J Am Geriatr Soc       Date:  2020-05-13       Impact factor: 5.562

Review 3.  Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression.

Authors:  Malcolm P Forbes; Adrienne O'Neil; Melissa Lane; Bruno Agustini; Nick Myles; Michael Berk
Journal:  Drugs Aging       Date:  2021-04-29       Impact factor: 3.923

4.  Interactive relationships of Type 2 diabetes and bipolar disorder with cognition: evidence of putative premature cognitive ageing in the UK Biobank Cohort.

Authors:  Elysha Ringin; David W Dunstan; Roger S McIntyre; Michael Berk; Neville Owen; Susan L Rossell; Tamsyn E Van Rheenen
Journal:  Neuropsychopharmacology       Date:  2022-10-15       Impact factor: 8.294

Review 5.  Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia.

Authors:  Gerwyn Morris; Luba Sominsky; Kenneth R Walder; Michael Berk; Wolfgang Marx; André F Carvalho; Chiara C Bortolasci; Michael Maes; Basant K Puri
Journal:  Mol Neurobiol       Date:  2022-03-26       Impact factor: 5.682

6.  Whole-exome sequencing in a subject with fluctuating neuropsychiatric symptoms, immunoglobulin G1 deficiency, and subsequent development of Crohn's disease: a case report.

Authors:  Harumi Jyonouchi; Lee Geng
Journal:  J Med Case Rep       Date:  2022-05-11

7.  Induced Ketosis as a Treatment for Neuroprogressive Disorders: Food for Thought?

Authors:  Gerwyn Morris; Basant K Puri; Andre Carvalho; Michael Maes; Michael Berk; Anu Ruusunen; Lisa Olive
Journal:  Int J Neuropsychopharmacol       Date:  2020-06-24       Impact factor: 5.176

Review 8.  Endothelial dysfunction in neuroprogressive disorders-causes and suggested treatments.

Authors:  Gerwyn Morris; Basant K Puri; Lisa Olive; Andre Carvalho; Michael Berk; Ken Walder; Lise Tuset Gustad; Michael Maes
Journal:  BMC Med       Date:  2020-10-19       Impact factor: 8.775

9.  The prevalence and related factors of metabolic syndrome in outpatients with first-episode drug-naive major depression comorbid with anxiety.

Authors:  Yinghua Zhong; Manji Hu; Qiang Wang; Zhendong Yang; Na Zhu; Fei Wang; Xiyan Zhang; Chengfang Zhang; Jie Min; Hao Wang; Fazhan Chen; Xudong Zhao; Xiangyang Zhang
Journal:  Sci Rep       Date:  2021-02-08       Impact factor: 4.379

Review 10.  Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review.

Authors:  Young Sup Woo; Hyun Kook Lim; Sheng-Min Wang; Won-Myong Bahk
Journal:  Int J Mol Sci       Date:  2020-09-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.